BioNexus Gene Lab Corp Common stock (BGLC)

BASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ

$1.24

-0.02 (-1.59%)

Market Cap: $3.70M

Last updated: Oct 16, 2026 at 1:54 PM ET

Earnings

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Jun 30, 2026Jun 26 Reported Aug 14, 2026Reported Aug 14	$-0.12	N/A	-	N/A	Beat	-	-	+64.7%
Mar 31, 2026Mar 26 Reported Apr 14, 2026Reported Apr 14	$-0.22	N/A	-	N/A	Beat	-	-	-649.7%
Dec 31, 2025Dec 25 Reported Dec 31, 2025Reported Dec 31	$-0.52	N/A	-	N/A	Beat	-	-	-169.7%
Sep 30, 2025Sep 25 Reported Nov 14, 2025Reported Nov 14	$-0.40	N/A	-	N/A	Beat	-	-	+46.6%
Jun 30, 2025Jun 25 Reported Aug 18, 2025Reported Aug 18	$-0.34	$0.00	-	N/A	Miss	-	-	-401.7%
Mar 31, 2025Mar 25 Reported Apr 15, 2025Reported Apr 15	$-0.03	N/A	-	N/A	Beat	-	-	+48.9%
Dec 31, 2024Dec 24 Reported Dec 31, 2024Reported Dec 31	$-0.19	N/A	-	N/A	Beat	-	-	-211.1%
Sep 30, 2024Sep 24 Reported Nov 15, 2024Reported Nov 15	$-0.75	N/A	-	N/A	Beat	-	-	+51.9%
Jun 30, 2024Jun 24 Reported Aug 14, 2024Reported Aug 14	$0.11	N/A	-	N/A	Beat	-	-	+162.9%
Mar 31, 2024Mar 24 Reported May 15, 2024Reported May 15	$-0.06	N/A	-	N/A	Beat	-	-	-23.1%
Dec 31, 2023Dec 23 Reported Mar 29, 2024Reported Mar 29	$0.17	N/A	-	N/A	Beat	-	-	+261.1%
Sep 30, 2023Sep 23 Reported Nov 20, 2023Reported Nov 20	$-1.56	N/A	-	N/A	Beat	-	-	-2807.5%
Jun 30, 2023Jun 23 Reported Jun 30, 2023Reported Jun 30	$-0.18	N/A	-	N/A	Beat	-	-	-85.2%
Mar 31, 2023Mar 23 Reported Mar 31, 2023Reported Mar 31	$-0.05	N/A	-	N/A	Beat	-	-	-497.5%
Dec 31, 2022Dec 22 Reported Dec 31, 2022Reported Dec 31	$-0.11	N/A	-	N/A	Beat	-	-	-273.4%
Sep 30, 2022Sep 22 Reported Nov 14, 2022Reported Nov 14	$-0.05	N/A	-	N/A	Beat	-	-	-125.8%
Jun 30, 2022Jun 22 Reported Aug 15, 2022Reported Aug 15	$-0.10	N/A	-	N/A	Beat	-	-	-5788.2%
Mar 31, 2022Mar 22 Reported Apr 6, 2022Reported Apr 6	$0.01	N/A	-	N/A	Beat	-	-	+5900.0%
Dec 31, 2021Dec 21 Reported Dec 31, 2021Reported Dec 31	$0.06	N/A	-	N/A	Beat	-	-	+3025.0%
Sep 30, 2021Sep 21 Reported Nov 15, 2021Reported Nov 15	$0.21	N/A	-	N/A	Beat	-	-	+1582.9%
Jun 30, 2021Jun 21 Reported Aug 12, 2021Reported Aug 12	$0.00	N/A	-	N/A	Beat	-	-	-26.1%
Mar 31, 2021Mar 21 Reported May 18, 2021Reported May 18	$0.00	N/A	-	N/A	Beat	-	-	+166.7%
Dec 31, 2020Dec 20 Reported Mar 30, 2021Reported Mar 30	$0.00	$0.00	-	N/A	Beat	-	-	-80.8%
Sep 30, 2020Sep 20 Reported Nov 3, 2020Reported Nov 3	$0.01	$0.00	-	N/A	Beat	-	-	+1466.7%
Jun 30, 2020Jun 20 Reported Aug 11, 2020Reported Aug 11	$0.00	$0.00	-	N/A	Beat	-	-	+866.7%
Mar 31, 2020Mar 20 Reported May 8, 2020Reported May 8	$-0.00	$0.00	-	N/A	Miss	-	-	+66.7%
Dec 31, 2019Dec 19 Reported Mar 31, 2020Reported Mar 31	$0.01	$0.00	-	N/A	Beat	-	-	+1400.0%
Sep 30, 2019Sep 19 Reported Nov 14, 2019Reported Nov 14	$-0.00	$0.00	-	N/A	Miss	-	-	+10.0%
Jun 30, 2019Jun 19 Reported Aug 9, 2019Reported Aug 9	$-0.00	$0.00	-	N/A	Miss	-	-	+76.9%
Mar 31, 2019Mar 19 Reported May 15, 2019Reported May 15	$-0.00	$0.00	-	N/A	Miss	-	-	-50.0%
Dec 31, 2018Dec 18 Reported Mar 31, 2019Reported Mar 31	$-0.00	$0.00	-	N/A	Miss	-	-	-115.1%
Sep 30, 2018Sep 18 Reported Dec 31, 2018Reported Dec 31	$-0.00	$0.00	-	N/A	Miss	-	-	+16.7%
Jun 30, 2018Jun 18 Reported Sep 30, 2018Reported Sep 30	$-0.00	$0.00	-	N/A	Miss	-	-	-
Mar 31, 2018Mar 18 Reported Jun 29, 2018Reported Jun 29	$-0.00	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2017Dec 17 Reported Mar 30, 2018Reported Mar 30	$0.01	$0.00	-	N/A	Beat	-	-	-
Sep 30, 2017Sep 17 Reported Dec 31, 2017Reported Dec 31	$-0.00	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-0.98	EV/EBITDA	N/A
Price/FCF	-4.26x	FCF Yield	-23.47%
Profitability
Profit Margin	-82.40%	Operating Margin	-398.70%
ROE	-33.70%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	-136.85x
Current Ratio	6.08x	Quick Ratio	5.28x
Trading Statistics
Beta	2.20	Avg Volume	10.10K
52-Week High	$5.89	52-Week Low	$1.07

Technical Indicators Dashboard

Moving Averages

SMA 10$1.29

SMA 20$1.34

SMA 50$1.45

SMA 200$2.11

EMA 10$1.29

EMA 20$1.33

EMA 50$1.45

EMA 200$2.16

MACD

Line: -0.05Signal: -0.06Hist: 0.00

ADX

ADX: 9.1+DI: 23.5-DI: 25.8

Aroon & PSAR

Aroon Up4.0

Aroon Down56.0

PSAR$1.41

Bollinger Bands

Upper Band$1.55

Lower Band$1.12

%B Position3225%(Upper)

Band Width0.28

RSI (14-Day)

Neutral

41.7

Momentum Oscillators

Stoch %K36.3

Stoch %D45.4

Williams %R-70.4

ROC (10d)3.3%

Momentum0.04

CCI (20d)-91.0

MFI (14d)59.1

Volatility Measures

ATR (14d)$0.11(8.6%)

StdDev (20d)0.11

Hist Vol75.9%(High)

Volume Flow

VWAP$1.22

OBV107.5M

AD Line-14.7M

CMF (20d)0.026

Volume Metrics

Avg Vol (20d)10.8K

Vol Ratio0.4x(Low)

VWMA (20d)$1.31

Pivot Points

R3$1.32

R2$1.30

R1$1.28

Pivot Point$1.26

S1$1.24

S2$1.22

S3$1.20

Advanced Oscillators

TSI-14.48

Ultimate Osc58.5

KST-138.35

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$76,156	$22,842	$483,760	$2.54M	$2.26M	$2.14M	$2.52M	$2.63M	$1.97M	$2.38M	$2.27M	$2.55M
Cost of Revenue	$39,955	$-3,111	$437,888	$2.17M	$1.82M	$1.77M	$1.37M	$2.05M	$1.13M	$1.99M	$2.01M	$2.20M
Gross Profit	$12,982	$-790	$-3,983	$377,685	$368,022	$343,493	$309,234	$326,536	$288,720	$365,031	$266,555	$354,332

Operating Expenses	$348,219	$597,386	$1.17M	$1.15M	$1.19M	$1.05M	$1.68M	$2.09M	$759,657	$404,968	$-1,178,311	$3.08M
R&D	$13,671	$14,487	$11,098	$14,876	$12,557	$12,139	$17,396	$10,442	$8,198	$11,475	$0	$0
SG&A	$298,526	$327,669	$181,095	$445,691	$516,790	$391,876	$165,932	$792,413	$558,829	$315,794	$-1,983,222	$3.08M
Operating Income	$-282,396	$-540,490	$-1,032,845	$-702,509	$-611,293	$-618,418	$-416,220	$-1,337,622	$259,168	$-79,028	$257,754	$-2,528,512

Interest Income	$21,183	$17,179	$9,079	$24,970	$62,136	$37,016	$-145,531	$143,614	$158,269	$128,895	$0	$0
Interest Expense	$4,055	$3,085	$3,272	$6,482	$4,879	$4,909	$5,812	$6,193	$4,480	$4,661	$4,183	$4,259
Income Before Tax	$-286,451	$-543,575	$-1,036,117	$-708,991	$-616,172	$-623,327	$-422,032	$-1,343,815	$254,688	$-83,689	$253,571	$-2,532,771
Income Tax Expense	$0	$0	$0	$0	$0	$0	$-40,565	$1,555	$55,584	$-20,068	$0	$76,418

Net Income	$-286,451	$-543,575	$-1,116,365	$-708,991	$-616,172	$-623,327	$-629,393	$-1,345,370	$199,104	$177,317	$308,463	$-2,609,189

EBITDA	$-227,565	$-482,844	$-984,691	$-616,778	$-491,994	$-549,146	$-356,554	$-1,267,747	$309,798	$-8,242	$448,639	$-2,266,099
EBIT	$-273,957	$-526,726	$-1,027,889	$-660,133	$-533,727	$-589,167	$-399,579	$-1,316,822	$278,341	$-37,828	$448,639	$-2,329,228

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about BGLC

News

BioNexus Gene Lab Corp. Plans to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence

BioNexus Gene Lab Corp. (BGLC) has signed an exclusive licensing agreement with Ruanyun Edai Technology Inc. (RYET) for its CogniAI artificial intelligence platform to develop AI applications for Malaysian healthcare....

www.marketscreener.com•Oct 8, 2026 1:40 AM ET10/8/26•Neutral

BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence

BioNexus Gene Lab Corp. (BGLC) has signed a definitive agreement with Ruanyun Edai Technology Inc. (RYET) for an exclusive 20-year licence to RYET's CogniAI artificial intelligence platform for Malaysian healthcare. This...

Yahoo Finance•Oct 7, 2026 8:40 AM ET10/7/26•Bullish

Malaysia raised public healthcare digitization funding to RM1 billion. BioNexus plans AI tools.

BioNexus Gene Lab Corp. (BGLC) has signed an exclusive Malaysian healthcare license with Ruanyun Edai Technology for its CogniAI artificial intelligence platform. BioNexus plans to develop AI applications for Malaysia's...

Stock Titan•Oct 7, 2026 8:32 AM ET10/7/26•Somewhat-Bullish

Ruanyun Edai Technology Inc. Grants Exclusive Cogni Ai License to Bionexus Gene Lab Corp. for Malaysian Healthcare

Ruanyun Edai Technology Inc. has granted BioNexus Gene Lab Corp. an exclusive license for its Cogni AI document-intelligence platform for healthcare in Malaysia. This agreement includes a reciprocal share exchange...

www.marketscreener.com•Oct 5, 2026 7:01 PM ET10/5/26•Neutral

Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury

BioNexus Gene Lab Corp., a Nasdaq-listed biotech firm, has become the first to implement an Ethereum-focused treasury strategy...

Yellow.com•Aug 15, 2026 11:41 AM ET8/15/26•Bullish

BGLC Valuation and Fair Value

P/E: -1.0x
P/FCF: -4.3x
P/B: -0.3x

See GNG's fair value

BGLC Profitability: Margins, ROIC and FCF

Gross margin: 12.3%
Operating margin: -398.7%
Net margin: -82.4%
ROE: -33.7%
FCF margin: -27.3%
FCF yield: -23.5%

BGLC Competitors

Company	Ticker
Origin Materials Inc	ORGN
SenesTech Inc	SNES
Gulf Resources, Inc. (NV) Common Stock	GURE
Capstone Holding Corp. Common Stock	CAPS
Trinseo SA	TSE
IT Tech Packaging Inc	ITP
Foremost Lithium Resource & Technology Ltd. Common stock	FMST
CN Energy Group Inc	CNEY

Sector: Basic Materials

BGLC Bull Case vs Bear Case

Bear case

BGLC has a -82.4% net profit margin.
BGLC's quarterly revenue changed -96.6% year over year.

BGLC Earnings: Beat Rate and Next Report

Beat rate: 4 of 8 quarters (50.0%)

Frequently Asked Questions About BGLC

Does BGLC pay dividends?

BioNexus Gene Lab Corp Common stock (BGLC) does not currently pay a regular dividend.

What is BGLC's market cap?

BioNexus Gene Lab Corp Common stock (BGLC) has a market capitalization of $3.70M with a current stock price of $1.24.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In